How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) posted its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10). Conatus Pharmaceuticals had a negative net margin of 52.42% and a negative trailing twelve-month return on equity of 48.22%.

What other stocks do shareholders of Conatus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP) , Trevena (TRVN) , PPL (PPL) , (CASC) (CASC) , Vaxart (VXRT) , Antares Pharma (ATRS) , Dextera Surgical (DXTR) , Novavax (NVAX) , Exelixis (EXEL) and Geron (GERN) .

NASDAQ:CNAT

Conatus Pharmaceuticals (CNAT) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CNAT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.05
▼
$0.15
50-Day Range: $0.56
▼
$1.34
52-Week Range: $0.23
▼
$1.07

Volume: 955 shs
Average Volume: 1.28 million shs
Market Capitalization: $4.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Conatus Pharmaceuticals alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Conatus Pharmaceuticals Stock (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

CNAT Stock News Headlines

April 3, 2023 | thestreet.com

Conatus Pharmaceuticals (CNAT) Stock Soars on Positive Liver Drug Trial Results

August 30, 2022 | thestreet.com

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know

See More Headlines

Receive CNAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conatus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/01/2020
Today: 4/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CNAT
CUSIP: N/A
CIK: 1383701
Web: www.conatuspharma.com
Phone: 858-376-2600
Fax: N/A
Employees: 30
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,390,000.00
Net Margins: -52.42%
Pretax Margin: N/A
Return on Equity: -48.22%
Return on Assets: -39.32%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.28
Quick Ratio: 16.28

Sales & Book Value

Annual Sales: $21.72 million
Price / Sales: 0.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.53 per share
Price / Book: 0.28

Miscellaneous

Outstanding Shares: 33,170,000
Free Float: N/A
Market Cap: $4.98 million
Optionable: Not Optionable
Beta: 1.84

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Steven J. Mento (Age 67)
Co-Founder, Pres, CEO & Director
Dr. Keith W. Marshall MBA (Age 51)
Ph.D., Exec. VP, COO & CFO
Dr. David T. Hagerty (Age 64)
Exec. VP of Clinical Devel.
Dr. Alfred P. Spada (Age 61)
Co-Founder, Exec. VP of R&D and Chief Scientific Officer
Mr. Alan R. Engbring
Exec. Director of Investor Relations & Corp. Communications

Key Competitors

View All Competitors

CNAT Stock Analysis - Frequently Asked Questions

How were Conatus Pharmaceuticals' earnings last quarter?: Conatus Pharmaceuticals Inc (NASDAQ:CNAT) posted its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10). Conatus Pharmaceuticals had a negative net margin of 52.42% and a negative trailing twelve-month return on equity of 48.22%.
What other stocks do shareholders of Conatus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), (CASC) (CASC), Vaxart (VXRT), Antares Pharma (ATRS), Dextera Surgical (DXTR), Novavax (NVAX), Exelixis (EXEL) and Geron (GERN).

This page (NASDAQ:CNAT) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Conatus Pharmaceuticals (CNAT) Stock Price, News & Analysis

About Conatus Pharmaceuticals Stock (NASDAQ:CNAT)

CNAT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CNAT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info